Correction to: Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial.

Durez, Patrick;Pavelka, Karel;Lazaro, Maria Alicia;Garcia-Kutzbach, Abraham;Vastesaeger, Nathan;et.al.
(2018) Clinical Rheumatology — Vol. 37, n° 7, p. 2017-2018 (2018)

Files

2018_Durez_Clin_Rheumatol_Correction.pdf
  • Open Access
  • Adobe PDF
  • 293.81 KB
Download

Details

Authors
  • Durez, PatrickUCLouvain
    Author
  • Pavelka, Karel
    Author
  • Lazaro, Maria Alicia
    Author
  • Garcia-Kutzbach, Abraham
    Author
  • Vastesaeger, Nathan
    Author
Show more
Abstract
Correction to: Clinical Rheumatology (2018) 37:1417–1420 (https://doi.org/10.1007/s10067-018-4074-6). The original publication contains two areas which require correcting. None of these errors change the results or conclusions of the article, but the authors wish to highlight the areas of change to the reader.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Durez, P., Pavelka, K., Lazaro, M. A., Garcia-Kutzbach, A., Moots, R. J., Amital, H., Govoni, M., & Vastesaeger, N. (2018). Correction to: Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial. Clinical Rheumatology, 37(7), 2017-2018. https://doi.org/10.1007/s10067-018-4131-1 (Original work published 2018)